Axitinib

Axitinib is a selective tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3. It is approved for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. Mediocon Inc supplies pharmaceutical-grade Axitinib meeting IP/BP/EP/USP standards.

Key Features

• Selective VEGFR tyrosine kinase inhibitor
• IP/BP/EP/USP compliant quality
• Advanced renal cell carcinoma treatment
• Suitable for oral tablet formulations

Applications

• Renal cell carcinoma tablets
• Oncology combination therapy
• Targeted cancer treatment manufacturing
• Clinical trial supplies

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings